bioMérieux (BIM) AGM 2026 summary

Opening remarks and agenda

• The meeting opened with a review of the 2025 activity and 2026 outlook, including presentations on SpinChip, environmental commitments, auditor reports, and resolutions for shareholder voting.

Financial performance review

• 2025 sales reached €4,070m, up 6.2% at constant exchange rates, with strong growth in all segments except immunoassays.

• Contributive EBIT rose to €728m (17.9% of sales), up 16% at constant rates, and free cash flow increased by 40% to €462m.

• Net adjusted EPS grew by 9%, and a dividend of €0.98 per share (+9%) was proposed.

• Investments totaled ~€330m, focused on automation and capacity expansion in the US and France.

Board and executive committee updates

• Renewal of Alexandre Mérieux’s mandate as director for four years and nomination of François Lacoste as director and Jean-Luc Bélingard as censor were proposed.

• The annual remuneration envelope for directors was set at €700,000.